Cargando…
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients
BACKGROUND: The use of the cardiovascular polypill, a fixed-dose combination treatment, is conceived to improve adherence. However, randomized controlled trials (RCTs) may overestimate it. Studies focusing on cerebrovascular disease and real-life efficacy compared with conventional treatment are lac...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747048/ https://www.ncbi.nlm.nih.gov/pubmed/33176324 http://dx.doi.org/10.1159/000511064 |
_version_ | 1783624914449727488 |
---|---|
author | Ros-Castelló, Victoria Natera-Villalba, Elena Gómez-López, Ana Sánchez-Sánchez, Arantxa Chico-García, Juan Luis García-Madrona, Sebastian Vera-Lechuga, Rocio Matute-Lozano, Consuelo de Felipe Mimbrera, Alicia Cruz-Culebras, Antonio Alonso-Canovas, Araceli Masjuan, Jaime |
author_facet | Ros-Castelló, Victoria Natera-Villalba, Elena Gómez-López, Ana Sánchez-Sánchez, Arantxa Chico-García, Juan Luis García-Madrona, Sebastian Vera-Lechuga, Rocio Matute-Lozano, Consuelo de Felipe Mimbrera, Alicia Cruz-Culebras, Antonio Alonso-Canovas, Araceli Masjuan, Jaime |
author_sort | Ros-Castelló, Victoria |
collection | PubMed |
description | BACKGROUND: The use of the cardiovascular polypill, a fixed-dose combination treatment, is conceived to improve adherence. However, randomized controlled trials (RCTs) may overestimate it. Studies focusing on cerebrovascular disease and real-life efficacy compared with conventional treatment are lacking. METHODS: This is a retrospective, hospital-based cohort study of acute ischaemic stroke patients who were prescribed a polypill (aspirin 100 mg, atorvastatin 20/40 mg, ramipril 2.5/5/10 mg) versus conventional treatment (aspirin 100 mg and other blood pressure/lipid-lowering agents) in secondary prevention (2017–2018). Clinical records were reviewed 90 days after discharge for stroke recurrence, vascular risk factor control, and safety. Adherence was assessed using the adapted Morisky-Green scale. RESULTS: A total of 104 patients were included (61% male; mean age 69.7 ± 13.9 years); 54 were treated with the polypill and 50 with conventional treatment. No baseline differences in clinical or demographic variables were detected. No recurrences were registered in the polypill group, compared to 1 recurrence in the conventional treatment group. A significant reduction of systolic blood pressure (SBP) was achieved in the polypill group (12.1 mm Hg) compared to the conventional treatment group (6.8 mm Hg) (p = 0.002). No significant differences were detected regarding the goal of LDL cholesterol ≤70 mg/dL (41 vs. 44%). The adverse events were mild and their frequency was similar in the two groups (9 vs. 2%, ns). Adherence was similarly good in the two groups (93 vs. 88%, ns). Polypill group adherence was similar to that reported in a previous meta-analysis of RCTs (93 vs. 84%, ns). CONCLUSION: In our experience, the cardiovascular polypill achieved a higher reduction in SBP levels and was well tolerated. Adherence was similar to that found in the previous literature, which is remarkable given the real-life setting of our study. |
format | Online Article Text |
id | pubmed-7747048 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-77470482020-12-24 Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients Ros-Castelló, Victoria Natera-Villalba, Elena Gómez-López, Ana Sánchez-Sánchez, Arantxa Chico-García, Juan Luis García-Madrona, Sebastian Vera-Lechuga, Rocio Matute-Lozano, Consuelo de Felipe Mimbrera, Alicia Cruz-Culebras, Antonio Alonso-Canovas, Araceli Masjuan, Jaime Cerebrovasc Dis Extra Original Paper BACKGROUND: The use of the cardiovascular polypill, a fixed-dose combination treatment, is conceived to improve adherence. However, randomized controlled trials (RCTs) may overestimate it. Studies focusing on cerebrovascular disease and real-life efficacy compared with conventional treatment are lacking. METHODS: This is a retrospective, hospital-based cohort study of acute ischaemic stroke patients who were prescribed a polypill (aspirin 100 mg, atorvastatin 20/40 mg, ramipril 2.5/5/10 mg) versus conventional treatment (aspirin 100 mg and other blood pressure/lipid-lowering agents) in secondary prevention (2017–2018). Clinical records were reviewed 90 days after discharge for stroke recurrence, vascular risk factor control, and safety. Adherence was assessed using the adapted Morisky-Green scale. RESULTS: A total of 104 patients were included (61% male; mean age 69.7 ± 13.9 years); 54 were treated with the polypill and 50 with conventional treatment. No baseline differences in clinical or demographic variables were detected. No recurrences were registered in the polypill group, compared to 1 recurrence in the conventional treatment group. A significant reduction of systolic blood pressure (SBP) was achieved in the polypill group (12.1 mm Hg) compared to the conventional treatment group (6.8 mm Hg) (p = 0.002). No significant differences were detected regarding the goal of LDL cholesterol ≤70 mg/dL (41 vs. 44%). The adverse events were mild and their frequency was similar in the two groups (9 vs. 2%, ns). Adherence was similarly good in the two groups (93 vs. 88%, ns). Polypill group adherence was similar to that reported in a previous meta-analysis of RCTs (93 vs. 84%, ns). CONCLUSION: In our experience, the cardiovascular polypill achieved a higher reduction in SBP levels and was well tolerated. Adherence was similar to that found in the previous literature, which is remarkable given the real-life setting of our study. S. Karger AG 2020-11-11 /pmc/articles/PMC7747048/ /pubmed/33176324 http://dx.doi.org/10.1159/000511064 Text en Copyright © 2020 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. |
spellingShingle | Original Paper Ros-Castelló, Victoria Natera-Villalba, Elena Gómez-López, Ana Sánchez-Sánchez, Arantxa Chico-García, Juan Luis García-Madrona, Sebastian Vera-Lechuga, Rocio Matute-Lozano, Consuelo de Felipe Mimbrera, Alicia Cruz-Culebras, Antonio Alonso-Canovas, Araceli Masjuan, Jaime Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients |
title | Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients |
title_full | Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients |
title_fullStr | Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients |
title_full_unstemmed | Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients |
title_short | Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients |
title_sort | use of the cardiovascular polypill in secondary prevention of cerebrovascular disease: a real-life tertiary hospital cohort study of 104 patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747048/ https://www.ncbi.nlm.nih.gov/pubmed/33176324 http://dx.doi.org/10.1159/000511064 |
work_keys_str_mv | AT roscastellovictoria useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT nateravillalbaelena useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT gomezlopezana useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT sanchezsanchezarantxa useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT chicogarciajuanluis useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT garciamadronasebastian useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT veralechugarocio useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT matutelozanoconsuelo useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT defelipemimbreraalicia useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT cruzculebrasantonio useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT alonsocanovasaraceli useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients AT masjuanjaime useofthecardiovascularpolypillinsecondarypreventionofcerebrovasculardiseaseareallifetertiaryhospitalcohortstudyof104patients |